Barclays PLC Acquires 124,650 Shares of Biohaven Ltd. (NYSE:BHVN)

Barclays PLC increased its stake in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 46.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 392,727 shares of the company's stock after buying an additional 124,650 shares during the quarter. Barclays PLC owned 0.39% of Biohaven worth $14,669,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Biohaven by 8.1% in the 4th quarter. Vanguard Group Inc. now owns 8,414,120 shares of the company's stock worth $314,267,000 after acquiring an additional 628,211 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Biohaven by 144.5% in the fourth quarter. JPMorgan Chase & Co. now owns 1,979,169 shares of the company's stock worth $73,922,000 after purchasing an additional 1,169,721 shares in the last quarter. Geode Capital Management LLC boosted its stake in Biohaven by 11.1% in the fourth quarter. Geode Capital Management LLC now owns 1,905,366 shares of the company's stock worth $71,182,000 after purchasing an additional 190,754 shares in the last quarter. ARS Investment Partners LLC grew its holdings in shares of Biohaven by 1.0% during the fourth quarter. ARS Investment Partners LLC now owns 1,040,712 shares of the company's stock worth $38,871,000 after purchasing an additional 10,473 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Biohaven in the fourth quarter valued at $33,711,000. Institutional investors and hedge funds own 88.78% of the company's stock.

Biohaven Price Performance

BHVN traded up $0.25 during mid-day trading on Wednesday, hitting $21.40. The stock had a trading volume of 2,301,708 shares, compared to its average volume of 1,112,738. Biohaven Ltd. has a 1-year low of $15.79 and a 1-year high of $55.70. The firm has a market capitalization of $2.18 billion, a price-to-earnings ratio of -2.29 and a beta of 1.33. The stock's fifty day simple moving average is $27.59 and its 200-day simple moving average is $38.15.

Biohaven (NYSE:BHVN - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported ($1.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.29). As a group, research analysts expect that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BHVN has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft set a $60.00 price objective on shares of Biohaven and gave the stock a "buy" rating in a report on Thursday, March 20th. Royal Bank of Canada reissued an "outperform" rating and issued a $61.00 price target on shares of Biohaven in a report on Tuesday, March 4th. Morgan Stanley reduced their price objective on Biohaven from $69.00 to $63.00 and set an "overweight" rating on the stock in a report on Friday, March 7th. JPMorgan Chase & Co. lowered their target price on Biohaven from $72.00 to $68.00 and set an "overweight" rating for the company in a research note on Wednesday, March 5th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $54.00 price target on shares of Biohaven in a research note on Tuesday, March 4th. Fourteen equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Biohaven has an average rating of "Buy" and an average target price of $62.77.

Insider Buying and Selling

In related news, Director John W. Childs bought 32,700 shares of Biohaven stock in a transaction that occurred on Tuesday, March 4th. The stock was purchased at an average cost of $30.47 per share, with a total value of $996,369.00. Following the purchase, the director now owns 2,320,571 shares in the company, valued at approximately $70,707,798.37. This trade represents a 1.43 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 16.00% of the stock is owned by company insiders.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.